Arguably the most boring step in genomics is the first one: normalization. Settled science. Scale + log. Move on.
Except that here's been a huge blind spot in the field. And it matters for AIxBio. A 🧵about what I think may be one of the most important papers I've written. 1/
NEON was shocked after seeing the $1,000,000 chrome-plated Maybach Kanye West gifted The Game. He got a full tour of it and even sat inside. I thought this was a joke but Kanye really gave him that car 😲
I've checked this paper out, as instructed. I was also interested in the main result for personal reasons: I'm 51 years old. Is it true that I've just gone through a major change? And that another one awaits me in just a few years?
Some comments on the paper in this thread 1/🧵
Earlier this week we carried out a preliminary analysis of our first @10xGenomics Xenium prime (5,000 gene) run. We had designed this experiment to get a sense of how the prime chemistry performed compared to the Xenium V1 chemistry.
"All models are wrong and yours are useless: making clinical prediction models impactful for patients"
With quite an interesting opener
https://t.co/5z2QCiHi21
I see we are getting to the stage of the discussion where people are starting to defend UMAP saying it can 'reveal patterns' or 'structure' in the data. Without ever specifying what precisely these patterns/structures represent. This is not surprising because hardly anybody 1/n
Looking forward to our next #globalimmuno talk this Wednesday, January 10th at 9am PST, noon EST, 4pm GMT by Dr. Michal Schwartz.
Title: “The immune system protects the healthy mind”
LINK: https://t.co/2Tdtm2zlSL
We need more studies like these!
"Thus, this study highlights the impact of quality control and differential analysis methods on the discovery of disease-associated genes and aims to refocus the AD research field away from spuriously identified genes."
https://t.co/1JjarEnU49
Important findings by Mulroney T.E et al, that will surely impact future mRNA-based therapeutics. N1-methylpseudouridine mRNA modification reduces immunogenicity, BUT also increases protein mistranslation resulting in potential off-target effects.
https://t.co/P3TrW2yzgx
New from my lab: we show that a clinical-stage oncology drug from Eli Lilly is mischaracterized, and its true anti-cancer target is EGFR.
We also show how in vitro drug assays can be misleading - cellular+genetic methods are needed to determine drug MOAs.
Huge thanks to Qi Lin and Dr. Heather Eaton for performing the revision expts, and to my mentor/supervisor Dr. Maya Shmulevitz @ShmulevitzL for helping push this story across the finish line! 2/2
🎆Final story from my PhD work published @JVirology. We uncover the pivotal role of p38MAPK signaling during oncolytic reovirus replication and show the p38b-MAPK11 isoform correlates with reovirus infection in various cancer cells and could be a potential prognostic marker 1/2
#jvirology Editor's Pick: Mohamed et al. (@ViroAdil, @Offey4, @ShmulevitzL) unravel the roles of p38 MAPK signaling during oncolytic reovirus infection & propose the inclusion of p38b(MAPK11) as a prognostic marker in patient stratification. https://t.co/cZe6DNYrRC
Interesting manuscript from Vincent Detours Lab @ULBruxelles "We demonstrated that in breast cancer any set of 100 genes or more selected at random has a 90% chance to be significantly associated with outcome." 🤯🤯
https://t.co/ArMeGJW8eG
New from my lab: we show that a clinical-stage oncology drug from Eli Lilly is mischaracterized, and its true anti-cancer target is EGFR. We also show how in vitro drug assays can be misleading - cellular+genetic methods are needed to determine drug MOAs.
https://t.co/xEhKNQHtMb